Abstract
LDL-cholesterol (LDL-C) target levels in patients with cardiovascular disease (CVD) are getting lower. New statin combinations will be more cost effective than present combinations and will help to achieve LDL-C targets. These and other drugs in development promise a new era in CVD prevention.
| Original language | English |
|---|---|
| Pages (from-to) | 33-42 |
| Number of pages | 10 |
| Journal | Medicine Today |
| Volume | 13 |
| Issue number | 1 |
| Publication status | Published - Jan 2012 |
